Franck Boccara
Prof Franck Boccara is an expert in Cardiology at Hôpital Saint-Antoine (France). As of October 2026, ScienceLeadR ranks Franck Boccara in the top 1% of experts worldwide for Dyslipidemias and Lipid Metabolism Disorders. Franck Boccara has authored 332 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 7 of them ongoing. SLR score: 1,404 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Endocrinology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1997 - 2026
Number : 332
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Four-Chamber Myocardial Strain to Predict Mortality in Pulmonary Embolism. PMID 42362047 — mortality, embolism, cardiology, pulmonary embolism, echocardiography, myocardial strain | Can J Cardiol | 2026 | 1 |
| Increased mortality in myocardial infarction after COVID-19 infection: more and more convincing data. PMID 42294972 — mortality, myocardial infarction, cardiovascular diseases, covid-19, infections | Eur J Prev Cardiol | 2026 | 0 |
| [Patient education in heart failure]. PMID 42227630 — quality of life, chronic disease, heart failure, heart, signs and symptoms, therapeutics, education, patient education as topic | Rev Prat | 2026 | 0 |
| A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit. PMID 42171985 — diabetes mellitus, hypertension, research, therapeutics, diabetes mellitus, type 2, single-pill combination | Cardiol Ther | 2026 | 0 |
| First quinquennium completed: highlights from EHJ Open 2025. PMID 42146872 | Eur Heart J Open | 2026 | 0 |
Clinical Studies 27
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An open label extension (OLE) trial to evaluate long term safety and tolerability of pelacarsen (TQJ230) 2024-519870-38-00 — safety, cardiovascular diseases | Phase 3 | Not yet recruiting | 2026 |
| A randomized double blind placebo controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high risk primary prevention patients (VICTORION 1 PREVENT) 2022-502779-40-00 — cardiovascular diseases, primary prevention | Phase 3 | Active not recruiting | 2023 |
| A Trial to Test How AZD0780 Affects Serious Heart Stroke or Vascular Problems in Patients with Heart Stroke or Vascular Disease or at High Risk for Such Issues 2025-520519-14-00 — stroke, heart, cardiovascular diseases, vascular diseases | Phase 3 | Recruiting | 2025 |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) NCT07157774 — lipoproteins, cardiovascular diseases, atherosclerosis, lipoprotein(a) | Phase 3 | Recruiting | 2025 |
| Detection and Follow up of Coronary Lesions in HeFH (DESTINY FH Study) NCT07427472 — hyperlipoproteinemia type ii, injections, contrast media, coronary artery disease, tomography, angiography, arteries, atherosclerosis, wounds and injuries, computed tomography angiography, hypercholesterolemia | N/A | Recruiting | 2026 |
LeadR Networks
Main global connection map